BG103278A - Медикаментозно лечение - Google Patents

Медикаментозно лечение

Info

Publication number
BG103278A
BG103278A BG103278A BG10327899A BG103278A BG 103278 A BG103278 A BG 103278A BG 103278 A BG103278 A BG 103278A BG 10327899 A BG10327899 A BG 10327899A BG 103278 A BG103278 A BG 103278A
Authority
BG
Bulgaria
Prior art keywords
medicamentous treatment
coronarovascular
hyperuricaemia
gout
monohydrate
Prior art date
Application number
BG103278A
Other languages
English (en)
Inventor
Peter Kelly
Stephan Jones
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG103278A publication Critical patent/BG103278A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Изобретението се отнася до използване на съединение или на негови фармацевтично приемливи соли, с формула, в която R1 и R2 независимо означават водород или метил, например N,N-диметил-1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин хидрохлорид, в даден случай под форма на монохидрат. Съединенията са полезни за намаляване нивото на пикочна киселинав човешкия организъм, например при хора, страдащи от или с риск от развитие на подагра, хиперурикемия или коронарно-съдови заболявания.
BG103278A 1996-09-25 1999-03-24 Медикаментозно лечение BG103278A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619962.5A GB9619962D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005034 WO1998013033A1 (en) 1996-09-25 1997-09-15 Medical treatment

Publications (1)

Publication Number Publication Date
BG103278A true BG103278A (bg) 2000-01-31

Family

ID=10800448

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103278A BG103278A (bg) 1996-09-25 1999-03-24 Медикаментозно лечение

Country Status (26)

Country Link
US (1) US6162831A (bg)
EP (1) EP1007023B1 (bg)
JP (1) JP2001501608A (bg)
KR (1) KR20000048568A (bg)
CN (1) CN1231604A (bg)
AT (1) ATE239460T1 (bg)
AU (1) AU722129B2 (bg)
BG (1) BG103278A (bg)
BR (1) BR9711414A (bg)
CA (1) CA2266438A1 (bg)
DE (1) DE69721838T2 (bg)
DK (1) DK1007023T3 (bg)
ES (1) ES2199374T3 (bg)
GB (1) GB9619962D0 (bg)
HR (1) HRP970519A2 (bg)
HU (1) HUP9904545A3 (bg)
IL (1) IL128851A (bg)
NO (1) NO991425L (bg)
NZ (1) NZ334668A (bg)
PL (1) PL332423A1 (bg)
PT (1) PT1007023E (bg)
SK (1) SK32199A3 (bg)
TR (1) TR199900649T2 (bg)
TW (1) TW415842B (bg)
WO (1) WO1998013033A1 (bg)
ZA (1) ZA978573B (bg)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
CZ20013284A3 (cs) * 1999-03-19 2002-10-16 Knoll Gmbh Farmaceutická kompozice pro léčbu osteoartritidy nebo dny
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US9655932B2 (en) * 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
JP2008506785A (ja) * 2004-07-21 2008-03-06 フロリダ大学 リサーチファウンデーション インコーポレイティッド インスリン抵抗性の治療及び予防のための組成物及び方法
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
US11179426B2 (en) 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1994000114A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
EP0708639A4 (en) * 1992-06-23 1997-08-20 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTTRAMINE
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
DE69721838D1 (de) 2003-06-12
US6162831A (en) 2000-12-19
GB9619962D0 (en) 1996-11-13
DK1007023T3 (da) 2003-08-25
BR9711414A (pt) 2000-04-25
HRP970519A2 (en) 1998-08-31
DE69721838T2 (de) 2004-01-22
ES2199374T3 (es) 2004-02-16
JP2001501608A (ja) 2001-02-06
EP1007023B1 (en) 2003-05-07
NO991425D0 (no) 1999-03-24
CN1231604A (zh) 1999-10-13
HUP9904545A3 (en) 2000-12-28
ATE239460T1 (de) 2003-05-15
PL332423A1 (en) 1999-09-13
NZ334668A (en) 2000-07-28
CA2266438A1 (en) 1998-04-02
IL128851A (en) 2001-08-26
ZA978573B (en) 1999-03-25
KR20000048568A (ko) 2000-07-25
NO991425L (no) 1999-03-24
TR199900649T2 (xx) 1999-07-21
PT1007023E (pt) 2003-08-29
WO1998013033A1 (en) 1998-04-02
IL128851A0 (en) 2000-01-31
SK32199A3 (en) 1999-12-10
HUP9904545A2 (hu) 2000-11-28
EP1007023A1 (en) 2000-06-14
AU722129B2 (en) 2000-07-20
TW415842B (en) 2000-12-21
AU4385197A (en) 1998-04-17

Similar Documents

Publication Publication Date Title
BG103278A (bg) Медикаментозно лечение
PH31220A (en) Medical treatment.
BG103277A (bg) Използване на сибутраминови аналози за предотвратяване развитието на диабет
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
WO2000056315A8 (en) Treatment of pain
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
MXPA01009467A (es) Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
MXPA03011193A (es) Nuevos compuestos utiles en enfermedad de reflujo.
MY133438A (en) Morpholinobenzamide salts
EP0266559A3 (en) Therapeutic agent for the treatment of peptic ulcer disease
AU4373785A (en) Dibenzyl-imidazole derivatives
MXPA01009461A (es) Tratamiento de osteoartritis.
MXPA01009463A (es) Tratamiento de hernia hiatial.
AU2001262786A1 (en) Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes